TSO3 adds the University of Rochester Medical Center to its Strategic Partner Facility ProgramThursday, January 5, 2017
Québec City, Québec – January 5, 2017 – TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, announced today that Highland Hospital of Rochester, NY (“the Hospital”), which is part of UR Medicine, the University of Rochester’s clinical enterprise, has joined its Strategic Partner Facility Program.
Under the Program, the Hospital and TSO3 have agreed to deploy multiple TSO3’s STERIZONE® VP4 Sterilizers in the Hospital, and the Hospital has agreed to evaluate the Sterilizer and provide TSO3 data and feedback regarding its use of the Sterilizer at the Hospital.
“We are pleased to see the deployment of multiple STERIZONE® VP4 Sterilizer systems into the UR Medicine health system,” noted Ric Rumble, TSO3’s President and CEO. “We will continue work toward adding key healthcare leaders to this important program to help improve existing sterilization practices and explore processes to enable the routine terminal sterilization of multi-channel flexible endoscopes.”
About the STERIZONE® VP4 Sterilizer
The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.
The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes - an industry first for any medical device sterilization process.
The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).
More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section at http://www.tso3.com/en/products/sterizone-vp4/.
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO3's sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the ability of the Company to obtain the required regulatory clearance to market its products on a worldwide basis; general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
- 30 -
Source: TSO3 Inc.
For further information
TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: email@example.com
TSO3 Inc., Glen Kayll, CFO, Tel: 418 651-0003, Email: firstname.lastname@example.org
Liolios Group, Inc., Scott Liolios, Tel: 949 574-3860, TOS@liolios.com
Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, email@example.com